论文部分内容阅读
目的:比较分析恶性肿瘤患者病情恶化前后与持续稳定时的蛋白质指纹。方法:选择应用CM10弱阳离子芯片结合表面增强飞行时间质谱(surface enhanced laser desorption/ionization time of flight mass spectrometry,SELDI-TOF-MS)技术检测的107例经手术治疗,且LGT指纹(指血清中出现质核比(M/Z):11000+H～12000+H的蛋白质指纹,设定为LGT阳性指纹,反之为阴性)在手术前为阴性的恶性肿瘤患者,随访1年,根据随访后LGT指纹仍为阴性组(95人)A组,和由阴性转变为阳性组(12人)B组。其中A组第1次检测结果设为A1组,第2次检测结果设为A2组;B组第1次检测结果设为B1组,第2次检测结果设为B2组。采用Protein Chip3.2.0和Biomarker Wizard3.1软件比较各组间有无差异指纹。结果:A1组-A2组:M/Z:2073、4116、2901、1558、4052、2048、1401、1298、1509、2888指纹上调,M/Z:3568、10050、2600、4629、9287、14822指纹下调;A1组-B1组:M/Z:8972、8460及8767指纹上调,M/Z:3192、3155、4326、4281、4381、3304、5448及2942指纹下调;A2组-B1组:M/Z:15851、15534、8460指纹上调,M/Z:3285、3304、3346、4178、3192、3266、951、5167、3930、4271、4052、4961、4259及2681指纹下调;B1组-B2组:M/Z:11648、11873、11489、11532及11405指纹上调,M/Z:8767指纹下调;A1组-B2组:M/Z:11618、11405、11648、11489、11532和11744指纹上调,无表达下调的指纹;A2组-B2组:M/Z:11489、11648、11405、11532、11318及11873指纹上调,无表达下调的指纹。结论:恶性肿瘤患者其LGT蛋白质指纹在疾病初期及持续稳定期均呈阴性时,LGT阳性表达是病情恶化的主要标识。本研究中,血清蛋白质指纹M/Z:8767上调和下调所表达的意义是不同的,尤其是在动态观察下,从有到消失及从无到出现,代表病情演变的两个不同结果,其意义仍需进一步研究证实。M/Z:8460蛋白质指纹表达上调,M/Z:3192、3304表达下调,可视为预示日后病情发生进展的蛋白质指纹。
OBJECTIVE: To compare and analyze the protein fingerprints of patients with malignant tumor before and after the deterioration of the patient’s condition. Methods: A total of 107 cases treated with CM10 weak cation chip combined with SELDI-TOF-MS technique were selected and treated with LGT fingerprinting (referring to the presence of serum (M / Z): 11000 + H ~ 12000 + H protein fingerprinting, set to LGT positive fingerprint, otherwise negative) in patients with negative before surgery for 1 year, according to follow-up LGT fingerprints Group A remained negative (95), and Group B changed from negative to positive (12). The first test result of group A was set as A1 and the second test result was set as A2. The first test result of group B was set as B1 and the second test result was set as B2. Protein Chip3.2.0 and Biomarker Wizard3.1 software were used to compare the differences between the groups fingerprints. Results: A1 group-A2 group: M / Z: 2073,4116,2901,1558,4052,2048,1401,1298,1509,2888 fingerprint up, M / Z: 3568,10050,2600,4629,9287,14822 fingerprints A2 group-B1 group: M / Z: 8972, 8460 and 8767 fingerprints up, M / Z: 3192,3155,4326,4281,4381,3304,5448 and 2942 fingerprint down; Z: 15851,15534,8460 Fingerprints up, M / Z: 3285,3304,3346,4178,3192,3266,951,5167,3930,4271,4052,4961,4259 and 2681 fingerprint down; B1 group-B2 group: M / Z: 11648,11873,11489,11532 and 11405 fingerprints up, M / Z: 8767 fingerprint down; A1 group-B2 group: M / Z: 11618,11405,11648,11489,11532 and 11744 fingerprint upregulation, no expression A2-Group B2: M / Z: 11489,11648,11405,11532,11318 and 11873 fingerprints up, no expression of down-regulated fingerprints. CONCLUSION: LGT-positive expression of LGT protein fingerprints in patients with malignant tumors is negative at the initial and stable stages of the disease. In this study, the significance of serum protein fingerprinting M / Z: 8767 up-regulation and down-regulation is different, especially in the dynamic observation, from to disappear and from scratch, representing two different results of disease evolution, which Significance still needs further study confirmed. M / Z: 8460 protein fingerprinting up-regulation, M / Z: 3192,3304 down regulation, can be seen as predicting future progress of the protein fingerprints.